Insider Selling: Shuttle Pharmaceuticals (NASDAQ:SHPH) Major Shareholder Sells $35,231.40 in Stock

Shuttle Pharmaceuticals Holdings, Inc. (NASDAQ:SHPH) major shareholder Financial Lp Hrt sold 10,580 shares of the business’s stock in a transaction that occurred on Tuesday, July 7th. The shares were sold at an average price of $3.33, for a total transaction of $35,231.40. Following the transaction, the insider owned 70,805 shares of the company’s stock, valued at approximately $235,780.65. This represents a 13.00% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Major shareholders that own more than 10% of a company’s shares are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Wednesday, July 8th, Financial Lp Hrt sold 18,531 shares of Shuttle Pharmaceuticals stock. The shares were sold at an average price of $3.52, for a total value of $65,229.12.
• On Monday, July 6th, Financial Lp Hrt sold 9,022 shares of Shuttle Pharmaceuticals stock. The stock was sold at an average price of $3.51, for a total value of $31,667.22.
• On Thursday, July 2nd, Financial Lp Hrt bought 7,851 shares of Shuttle Pharmaceuticals stock. The stock was acquired at an average price of $3.54 per share, for a total transaction of $27,792.54.
• On Wednesday, July 1st, Financial Lp Hrt bought 3,959 shares of Shuttle Pharmaceuticals stock. The stock was bought at an average cost of $3.30 per share, with a total value of $13,064.70.
• On Tuesday, June 30th, Financial Lp Hrt purchased 6,755 shares of Shuttle Pharmaceuticals stock. The shares were bought at an average cost of $3.23 per share, for a total transaction of $21,818.65.
• On Monday, June 29th, Financial Lp Hrt acquired 25,836 shares of Shuttle Pharmaceuticals stock. The stock was bought at an average cost of $3.44 per share, with a total value of $88,875.84.

Shuttle Pharmaceuticals Stock Down 11.0%

Shares of NASDAQ SHPH traded down $0.36 during midday trading on Friday, reaching $2.92. 67,573 shares of the company were exchanged, compared to its average volume of 2,340,694. The stock’s 50-day moving average price is $5.01 and its 200-day moving average price is $10.13. The stock has a market cap of $1.87 million, a P/E ratio of -0.06 and a beta of 0.29. Shuttle Pharmaceuticals Holdings, Inc. has a one year low of $2.90 and a one year high of $55.90.

Institutional Trading of Shuttle Pharmaceuticals

Several institutional investors have recently added to or reduced their stakes in SHPH. Connective Capital Management LLC acquired a new stake in Shuttle Pharmaceuticals during the 3rd quarter valued at approximately $357,000. Ikarian Capital LLC bought a new stake in shares of Shuttle Pharmaceuticals in the 4th quarter valued at $124,000. Boothbay Fund Management LLC bought a new stake in shares of Shuttle Pharmaceuticals in the 4th quarter valued at $37,000. Finally, Geode Capital Management LLC acquired a new stake in shares of Shuttle Pharmaceuticals during the fourth quarter worth $26,000. 4.58% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of equities analysts have issued reports on the company. Wall Street Zen raised Shuttle Pharmaceuticals to a “sell” rating in a report on Saturday, July 4th. Weiss Ratings upgraded Shuttle Pharmaceuticals from a “sell (e)” rating to a “sell (e+)” rating in a report on Tuesday, June 30th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat.com, the company has an average rating of “Sell”.

Shuttle Pharmaceuticals Company Profile

Shuttle Pharmaceuticals Holdings, Inc, a clinical stage pharmaceutical company, develops novel therapies to cure cancers. It develops Ropidoxuridine, an oral halogenated pyrimidine to treat patients with brain tumors and sarcomas SP-1-161, an HDAC inhibitor that initiates the mutated in ataxia-telangiectasia response pathway for radiation sensitizing cancer cells and protecting normal cells; SP-2-225, a pre-clinical class IIb that effects on the regulation of the immune system; and SP-1-303, a pre-clinical selective Class I HDAC for the treatment of ER positive cancers .